Clinical Trial Update: A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

View source ↗

Summary

Pfizer-sponsored clinical trial evaluating enzalutamide versus abiraterone in metastatic castration-resistant prostate cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Neoplasms, Castration-Resistant | Status: COMPLETED | Results posted: 2026-02-25